News and Announcements
Universal Biosensors Increases Revenue by 36% to $14.3m
- Published August 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Universal Biosensors (ASX:UBI) has recently announced its financial results for the first half of 2017. For the first six months, total revenue increased by 36% to $14.3 million, driven by both of UBI’s leading products – OneTouch® Verio® blood glucose strips and Xprecia Stride™ Coagulation Analyser test strips.
KEY TAKEAWAYS:
- Total revenue of $14.3 million in H1 2017, up 36% on H1 2016
- Xprecia Stride™ revenues, $2.3 million in H1 2017
- Gross margin and cost containment deliver net profit of $2.5 million in H1 2017
- Positive operating cash flows resulting in cash balance of $20 million as at 30 June 2017
Interim Chief Executive Officer Andrew Denver said: “We are pleased that we have continued on our positive growth trajectory of delivering profits and cash flows for our shareholders. Xprecia Stride™ coagulation test strips are beginning to make an important contribution to our revenues following full market release and the commencement of sales activities in the U.S. in the second quarter. Our strong track record of innovation and partnerships in the Point-of-Care diagnostics space, in combination with our sound financial position, leaves us well placed to capitalise on future growth opportunities.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
